Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

[1]  J. Werth,et al.  Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1) , 2020, American Journal of Clinical Dermatology.

[2]  Belinda Sheary.  Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use , 2018, Dermatitis : contact, atopic, occupational, drug.

[3]  J. Fowler,et al.  Long‐term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis , 2017, Journal of the American Academy of Dermatology.

[4]  M. Lebwohl,et al.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. , 2016, Journal of the American Academy of Dermatology.

[5]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. , 2014, Journal of the American Academy of Dermatology.

[6]  S. Spector,et al.  Atopic dermatitis: a practice parameter update 2012. , 2013, The Journal of allergy and clinical immunology.

[7]  T. Bieber.  Atopic dermatitis. , 2010, Annals of dermatology.

[8]  Thomas Bieber,et al.  Atopic dermatitis. , 2008, The New England journal of medicine.

[9]  R. Schwartz,et al.  Adverse effects of topical glucocorticosteroids. , 2006, Journal of the American Academy of Dermatology.

[10]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.